B+
Bull case
30%
Probability
Target price
$13.00
+56.8% vs current
CRMD
CorMedixBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$10.50
+26.7% vs current
B-
Bear case
25%
Probability
Target price
$6.50
-21.6% vs current
AI sentiment snapshot
Latest data as of 2026-07-11
Recent news sentiment (30D)
+0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+67.3
Score
AI commentary
Primary-source evidence quality is strong because the thesis is anchored by the May 14 earnings 8-K and the July 2 company 8-K [#SEC-8K-2026-05-14] [#8-K-2026-07-02]. News flow around Q1 was positive, but trusted post-print analyst revision detail is still unavailable in the packet, social context is not usable, and forward visibility still depends on a few concentrated operating and regulatory milestones. That keeps CRMD in a monitoring-style cautious positive bucket rather than a fully validated rerating.
RankAlpha Sentiment Codex - 2026-07-11
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-15catalystRaised 2026 guidance now has to hold through the next operating check-inHigh impact
The key near-term setup is whether the strong Q1 trajectory proves durable after management raised full-year 2026 net revenue guidance to $325-$345 million and adjusted EBITDA guidance to $115-$135 million, supported by strong DefenCath demand and profitability in the May 14 earnings release [#SEC-8K-2026-05-14].
2026-12-31eventREZZAYO prophylaxis sNDA preparation is the clearest pipeline rerating leverHigh impact
CorMedix said positive Phase III ReSPECT topline results support preparation for an FDA sNDA submission in 2H 2026 for REZZAYO prophylaxis, with a targeted 2027 expanded-indication launch if approved, giving the story a second commercial leg beyond DefenCath [#SEC-8K-2026-05-14].
2028-12-31catalystTPN Phase 3 progress remains real optionality but has pushed outHigh impact
Management said the taurolidine/heparin catheter lock Phase 3 study in TPN patients is still enrolling, with new study sites and a proposed FDA protocol amendment intended to broaden enrollment, but completion is trending to 2028, which preserves upside while keeping the payoff distant [#SEC-8K-2026-05-14].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-11 • Updated nightlySource: Internal modelMethodology